CO2018003960A2 - Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2 - Google Patents
Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2Info
- Publication number
- CO2018003960A2 CO2018003960A2 CONC2018/0003960A CO2018003960A CO2018003960A2 CO 2018003960 A2 CO2018003960 A2 CO 2018003960A2 CO 2018003960 A CO2018003960 A CO 2018003960A CO 2018003960 A2 CO2018003960 A2 CO 2018003960A2
- Authority
- CO
- Colombia
- Prior art keywords
- galgt2
- associated virus
- recombinant adeno
- nucleic acid
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01165—N-Acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase (2.4.1.165)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a la administración de virus adeno-asociado recombinante (rAAV) de un polinucleótido GALGT2. La divulgación proporciona rAAV y métodos de uso de rAAV para la terapia génica GALGT2 de trastornos neuromusculares. Los trastornos neuromusculares de ejemplo incluyen, pero no se limitan a, distrofias musculares tales como Distrofia muscular de Duchenne, Distrofia muscular congénita 1A y Distrofia muscular de la columna y extremidades 2D.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220107P | 2015-09-17 | 2015-09-17 | |
US201562221068P | 2015-09-20 | 2015-09-20 | |
US201662301260P | 2016-02-29 | 2016-02-29 | |
PCT/US2016/052051 WO2017049031A1 (en) | 2015-09-17 | 2016-09-16 | Methods and materials for galgt2 gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018003960A2 true CO2018003960A2 (es) | 2018-10-10 |
Family
ID=58289891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0003960A CO2018003960A2 (es) | 2015-09-17 | 2018-04-13 | Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2 |
Country Status (15)
Country | Link |
---|---|
US (2) | US10980897B2 (es) |
EP (1) | EP3350331A4 (es) |
JP (2) | JP7338970B2 (es) |
KR (1) | KR20180084747A (es) |
CN (1) | CN108136049A (es) |
AU (2) | AU2016323575B2 (es) |
BR (1) | BR112018005177A2 (es) |
CA (1) | CA2998636A1 (es) |
CO (1) | CO2018003960A2 (es) |
EA (1) | EA201890543A1 (es) |
HK (1) | HK1257519A1 (es) |
IL (1) | IL258005A (es) |
MX (1) | MX2018003234A (es) |
SA (1) | SA518391113B1 (es) |
WO (1) | WO2017049031A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45477A (fr) | 2016-04-15 | 2019-02-20 | Res Inst Nationwide Childrens Hospital | Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire |
US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
CN111433367A (zh) | 2017-10-20 | 2020-07-17 | 全国儿童医院研究所 | Nt-3基因疗法的方法和材料 |
EP3807309A1 (en) * | 2018-06-18 | 2021-04-21 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies |
EP4051324A4 (en) * | 2019-10-28 | 2023-11-29 | University Of Florida Research Foundation, Incorporated | GENE THERAPY VECTORS |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DK0733103T3 (da) | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
JPH10511264A (ja) | 1994-12-06 | 1998-11-04 | ターゲティッド ジェネティックス コーポレイション | 高力価組換えaavベクターの生成のためのパッケージング細胞株 |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
EP0847442A1 (en) | 1995-08-30 | 1998-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
ATE380037T1 (de) | 1996-09-06 | 2007-12-15 | Univ Pennsylvania | Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
AU2001255575B2 (en) | 2000-04-28 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
US20100267575A1 (en) * | 2006-10-17 | 2010-10-21 | Childrens Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
-
2016
- 2016-09-16 EP EP16847351.0A patent/EP3350331A4/en active Pending
- 2016-09-16 JP JP2018513504A patent/JP7338970B2/ja active Active
- 2016-09-16 AU AU2016323575A patent/AU2016323575B2/en active Active
- 2016-09-16 WO PCT/US2016/052051 patent/WO2017049031A1/en active Application Filing
- 2016-09-16 MX MX2018003234A patent/MX2018003234A/es unknown
- 2016-09-16 KR KR1020187010628A patent/KR20180084747A/ko not_active Application Discontinuation
- 2016-09-16 CN CN201680054261.9A patent/CN108136049A/zh active Pending
- 2016-09-16 CA CA2998636A patent/CA2998636A1/en active Pending
- 2016-09-16 BR BR112018005177A patent/BR112018005177A2/pt active Search and Examination
- 2016-09-16 EA EA201890543A patent/EA201890543A1/ru unknown
- 2016-09-16 US US15/759,474 patent/US10980897B2/en active Active
-
2018
- 2018-03-11 IL IL258005A patent/IL258005A/en unknown
- 2018-03-13 SA SA518391113A patent/SA518391113B1/ar unknown
- 2018-04-13 CO CONC2018/0003960A patent/CO2018003960A2/es unknown
- 2018-12-21 HK HK18116463.4A patent/HK1257519A1/zh unknown
-
2021
- 2021-03-16 US US17/203,232 patent/US20210220484A1/en active Pending
- 2021-11-05 JP JP2021180893A patent/JP2022010079A/ja active Pending
-
2023
- 2023-01-31 AU AU2023200499A patent/AU2023200499A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017049031A1 (en) | 2017-03-23 |
CN108136049A (zh) | 2018-06-08 |
SA518391113B1 (ar) | 2022-10-25 |
AU2016323575A1 (en) | 2018-04-05 |
EA201890543A1 (ru) | 2018-08-31 |
JP2022010079A (ja) | 2022-01-14 |
CA2998636A1 (en) | 2017-03-23 |
AU2023200499A1 (en) | 2023-06-15 |
JP2018527365A (ja) | 2018-09-20 |
US20180250423A1 (en) | 2018-09-06 |
MX2018003234A (es) | 2018-09-07 |
KR20180084747A (ko) | 2018-07-25 |
BR112018005177A2 (pt) | 2018-10-09 |
EP3350331A1 (en) | 2018-07-25 |
US10980897B2 (en) | 2021-04-20 |
EP3350331A4 (en) | 2019-01-23 |
US20210220484A1 (en) | 2021-07-22 |
IL258005A (en) | 2018-05-31 |
JP7338970B2 (ja) | 2023-09-05 |
HK1257519A1 (zh) | 2019-10-25 |
AU2016323575B2 (en) | 2022-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018003960A2 (es) | Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2 | |
CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
CY1123853T1 (el) | Ρυθμιστες nrf2 | |
BR112018011881A2 (pt) | proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus | |
EA201890999A1 (ru) | Вакцина против вируса простого герпеса | |
CL2016001579A1 (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos. | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
PH12016501151A1 (en) | Nrf2 regulators | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
PE20150163A1 (es) | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav | |
EA201790781A2 (ru) | Противовирусные соединения | |
BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
EA201790963A1 (ru) | Противовирусные соединения | |
EA201592014A1 (ru) | Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса | |
BR112019024747A2 (pt) | formulações de dose fixa | |
EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
CR20160512A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
MX355267B (es) | Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico. | |
EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
CL2014003464A1 (es) | Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa). | |
EA201790570A1 (ru) | Модуляторы р2х7 |